New CDC guidance on Influenza vaccination!! All should recv, ideally in September or October. Immunocompromised (by meds or Dx) should recv Trivalent inactivated (IIV3s) & trivalent recombinant vaccine (RIV3), but not the live virus vaccine (LAIV3) https://t.co/r7euIb3BV9 https://t.co/Tx2pU2Onng

All in the Family (8.23.2024) Dr. Jack Cush picks highlight reports from the past week on RheumNow, with reports on the challenge of lupus nephritis, perplexing skin issues, you don't know JAK (about Tyk) and the value of a good family history. https://t.co/gwM77mJCnr https://t.co/HOGnymjhSZ

ANCA-associated vasculitis analysis of 6 European registries, 3868 pts (2434 GPA, 1434 MPA), age ~57 yrs. Identified 5 clusters: 3 w/ renal dz a) variable ANCA, Hi CRP & Cr; b) MPO+; c) PR3+ & 2 extrarenal 1) PR3+ multisystem; 2) ENT w/ low CRP. Clusters better predicted outcomes… https://t.co/20O58AAYAa https://t.co/KF6PTVfcRw

Global Rheumatoid Arthritis Market estimated to be worth USD 22.77 billion in 2021 and is predicted to expand to USD 33.30 billion by 2030, with annual growth of 4.5% during the forecast period 2022-2030. https://t.co/J64mVxY4Ia https://t.co/6zg5g6KRdJ

Cohort study shows GERD in 1539/1632 (94%) #SSc patients & 450/469 (96%) of SSc-ILD pts. GERD didnt influence ILD Dx or severity. But GERD Rx (PPI, H2RA) assoc w/ improved survival in those Scleroderma pts with ILD (p = 0.002) https://t.co/stQkpbmBCP https://t.co/e4BBz5c0av

New $$$ drugs are NOT usually steroid sparing, but a single center 716 RA pt study compared JAKi (n 156) vs bDMARDs (560) starts; JAKi assoc w/ more rapid GC reduction in1st 6 mos & 60% higher odds of GC D/C (adj OR 1.63) (>50% vs 40% @12 mos) https://t.co/shiDytQeBU https://t.co/dCjyw21uLd

Among spondyloarthritis patients with clinical enthesitis, 68% had no ‘active enthesitis’ on ultrasound. Conversely, of those without signs of clinical enthesitis, 15% showed subclinical enthesitis on ultrasound ↓ https://t.co/aVEvOmcEHK

The new Covid KP.2 booster vaccines are becoming available throughout the US. Besides high-risk (e.g. age 65+, immunocompromised, comorbidities), one of the most important reasons to get boosted, often overlooked, is to reduce #LongCovid risk by ~50%. Agree with Marks at FDA… https://t.co/SgX7JiPRzH https://t.co/i0W4xadxjW

Check out a NEW review on the dichotomy of #glucocorticosteroids treatment in #rheumaticdiseases by @maurizio_cutolo and team 👉https://t.co/6c08ucQlDN 👨‍🎓Glucocorticosteroids - a double-edged sword https://t.co/VdKlPzFpOb

RISE registry study shows Prednisone Rx before rheum consult ends up with more long-term Pred. 1,733 RA pts; 715 on GC (41% 0.5-2 mos before rheum care). mean GC use =157 d. GC before rheum care associated with longer GC use https://t.co/UpeK4hwIN0 https://t.co/F8cuoX0ACq